NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal Nos. 75, 106 & 200; Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Merck, Sharp & Dohme	Allied Health Professionals Federation
(peginterferon alfa-2b, ribavirin)	Board of Community Health Councils in
Roche Products (peginterferon alfa-	Wales
2a, ribavirin)	 British National Formulary
	Care Quality Commission
Patient/carer groups	Commissioning Support Appraisals
 Action on Hepatitis C 	Service
Addaction	Department of Health, Social Services
Addiction Today (Addiction Recovery	and Public Safety for Northern Ireland
Network)	Drugs Action Scotland
Adfam	Healthcare Improvement Scotland
Afiya Trust	Medicines and Healthcare Products
 African Health Policy Network 	Regulatory Agency
Alliance	National Association of Primary Care
• AVERT	 National Pharmacy Association
Black Health Agency	NHS Alliance
British Liver Trust	NHS Commercial Medicines Unit
Compass UK	NHS Confederation
Drugscope	Scottish Medicines Consortium
 Equalities National Council 	
 The Gay Men's Health Charity 	Comparator manufacturers
Haemophilia Alliance	 Janssen (telaprevir)
Haemophilia Society	 Merck, Sharp & Dohme (boceprevir)
Hepatitis A-Z	
Hepatitis C Trust	Relevant research groups
 Muslim Council of Britain 	Centre for Sexual Health & HIV
Muslim Health Network	Research
 NAM publications 	Cochrane Hepato-biliary Group
 National AIDS Trust 	Foundation for Liver Research
National Hepatitis C Resource Centre	Health Research Authority
Positively UK	MRC Clinical Trials Unit
Rehabilitation for Addicted Prisoners	National Institute for Health Research
Trust (RAPt)	Research Institute for the Care of Older
 South Asian Health Foundation 	People
 Specialised Healthcare Alliance 	Accomment Crown
	Assessment Group

National Institute for Health and Care Excellence

NICE Technology Appraisal Nos. 75, 106 & 200; Peginterferon alfa and ribavirin for the treatment of chronic hepatitis Issue date: October 2013

National Institute for Health and Care Excellence NICE Technology Appraisal Nos. 75, 106 & 200; Peginterferon alfa and ribavirin for the treatment of chronic hepatitis Issue date: October 2013 Page 2 of 2

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.